Akari Therapeutics Stock Price, News & Analysis (NASDAQ:AKTX) $3.12 -0.03 (-0.95%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$3.06▼$3.2650-Day Range$2.91▼$3.8852-Week Range$2.81▼$11.43Volume6,794 shsAverage Volume8,595 shsMarket Capitalization$17.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media About Akari Therapeutics Stock (NASDAQ:AKTX)Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Read More AKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKTX Stock News HeadlinesDecember 2, 2023 | investing.comAkari Therapeutics (AKTX) Earnings Dates & ReportsDecember 2, 2023 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.comDecember 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 1, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Poised to End Week Flat in Friday TradingDecember 1, 2023 | americanbankingnews.comShort Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Declines By 36.0%November 28, 2023 | sg.finance.yahoo.comAkari Therapeutics, Plc (CLA.F)November 24, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Climb Higher FridayNovember 16, 2023 | finance.yahoo.comAkari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceDecember 9, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 14, 2023 | msn.comTravel, Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher TuesdayNovember 6, 2023 | finance.yahoo.comAkari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceOctober 3, 2023 | finance.yahoo.comPresenting on the Emerging Growth Conference 63 Day 1 on October 4 Register NowSeptember 29, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Reports First Half 2023 Financial Results and HighlightsSeptember 29, 2023 | finance.yahoo.comAkari Therapeutics Reports First Half 2023 Financial Results and HighlightsSeptember 27, 2023 | finance.yahoo.comAkari Therapeutics to Present at Emerging Growth ConferenceSeptember 21, 2023 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax CreditSeptember 19, 2023 | finance.yahoo.comAkari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet NeedsSeptember 5, 2023 | finance.yahoo.comAkari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementAugust 31, 2023 | msn.comAkari Therapeutics Plc - ADR (AKTX) Price Target Increased by 1900.00% to 56.10August 21, 2023 | finance.yahoo.comBritish pharma opens U.S. headquarters in BostonAugust 18, 2023 | finance.yahoo.comAkari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical TrialsAugust 17, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces ADS Ratio ChangeAugust 15, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics, Plc Announces ADS Ratio ChangeAugust 15, 2023 | msn.comAkari Therapeutics announces ADS ratio changeAugust 15, 2023 | finance.yahoo.comAkari Therapeutics, Plc Announces ADS Ratio ChangeAugust 2, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory AffairsAugust 2, 2023 | finance.yahoo.comAkari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory AffairsSee More Headlines Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2020Today12/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKTX CUSIPN/A CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book6.50Miscellaneous Outstanding Shares5,650,000Free Float2,159,000Market Cap$17.63 million OptionableNot Optionable Beta1.13 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Rachelle Suzanne Jacques (Age 52)President, CEO & Director Comp: $1.38MMs. Wendy F. DiCicco CPA (Age 56)Interim Chief Financial Officer Ms. Melissa Bradford-Klug (Age 53)Chief Operating Officer Dr. Miles Nunn (Age 54)Chief Scientific Officer Dr. John F. Neylan III (Age 70)M.D., Executive VP & Chief Medical Officer Ms. Beth-Anne LangSenior Vice President of Regulatory AffairsAnnie MackFinancial ControllerMore ExecutivesKey CompetitorsRedHill BiopharmaNASDAQ:RDHLNeuroBo PharmaceuticalsNASDAQ:NRBOMainz BiomedNASDAQ:MYNZLisata TherapeuticsNASDAQ:LSTAIndaptus TherapeuticsNASDAQ:INDPView All CompetitorsInstitutional OwnershipSabby Management LLCSold 7,214,040 shares on 11/15/2023Ownership: 3.152%View All Institutional Transactions AKTX Stock Analysis - Frequently Asked Questions How have AKTX shares performed in 2023? Akari Therapeutics' stock was trading at $9.3980 at the beginning of the year. Since then, AKTX shares have decreased by 66.8% and is now trading at $3.12. View the best growth stocks for 2023 here. Are investors shorting Akari Therapeutics? Akari Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 11,200 shares, a decrease of 36.0% from the October 31st total of 17,500 shares. Based on an average daily volume of 15,200 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.2% of the company's shares are short sold. View Akari Therapeutics' Short Interest. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics, Plc (NASDAQ:AKTX) announced its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00. When did Akari Therapeutics' stock split? Akari Therapeutics shares reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX). Who are Akari Therapeutics' major shareholders? Akari Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.15%). View institutional ownership trends. How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AKTX) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.